Approval · Notice of Compliance 9624 · 2008
AVAMYS: Notice of Compliance 9624
Issued June 13, 2008
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 9624
- Date
- June 13, 2008
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indications: treatment of perennial allergic rhinitis and its associated symptoms in patients 12 years of age and older. treatment of seasonal allergic rhinitis in children from 2 to 11 years of age.
- Therapeutic class
- Corticosteroid
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| AVAMYS | Not yet assigned | — |
Medicinal ingredients
- FLUTICASONE FUROATE 27.5 MCG per SPR